Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
On Tuesday, KeyBanc Capital Markets initiated coverage on shares of Lifestance Health Group (NASDAQ:LFST), a behavioral health company, with an Overweight rating and set a price target of $9.00. The coverage launch is based on the firm's positive outlook for the company's growth prospects. Currently trading at $6.51, the stock sits between analyst targets ranging from $8 to $11. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculations.
KeyBanc analysts anticipate that Lifestance Health Group will experience mid-teens organic top-line growth over the next few years. This outlook aligns with the company's impressive 18.5% revenue growth in the last twelve months and strong historical performance, with a five-year revenue CAGR of 43%. This growth is expected to be mainly fueled by an increase in visit volumes due to the addition of more clinicians and an improvement in total revenue per visit, which is likely to arise from better reimbursement rates from payors.
The analysts also predict that the company will see margin expansion, attributed to a recently optimized real estate footprint, enhanced clinician productivity, introduction of higher-margin specialty offerings, and ongoing cost efficiencies achieved through technology improvements.
A significant aspect of Lifestance Health Group's business strategy, as highlighted by KeyBanc, is the company's acceptance of over 150 different insurances. This wide range of accepted insurances is believed to contribute to higher patient retention and lower customer acquisition costs, leading to less revenue volatility and broader profit margins.
Furthermore, Lifestance Health Group's approach to treatment, which includes both virtual and in-person visits, stands out as a unique feature. Approximately 70% of patient visits are conducted virtually, while the remaining 30% take place at one of the company's more than 550 centers, which are spread across 33 states. This dual-channel offering is seen as a key differentiator for the company in the behavioral health space. With its next earnings report due on May 7, 2025, investors seeking deeper insights can access comprehensive analysis and valuation metrics through InvestingPro's detailed research reports, which cover over 1,400 US stocks including LFST.
In other recent news, LifeStance Health Group Inc. reported its fourth-quarter 2024 earnings, surpassing analysts' expectations with an earnings per share (EPS) of -$0.01, compared to the forecasted -$0.0383. The company's revenue for the quarter reached $325.5 million, exceeding the anticipated $313.91 million. LifeStance Health demonstrated a 16% year-over-year revenue growth and achieved its first-ever double-digit EBITDA margin. The company also reported a significant 62% increase in adjusted EBITDA, reaching $33 million for the quarter. Looking forward, LifeStance Health projects 2025 revenue between $1.400 billion and $1.440 billion, with adjusted EBITDA expected to range from $130 million to $150 million. The company plans to open 25-30 new centers in 2025 and anticipates achieving positive net income by 2026. Additionally, LifeStance Health has undergone leadership changes, with Dave Borden appointed as the new CEO, succeeding Ken Burdick, who will transition to the role of Executive Chairman.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.